{
  "docId": "019de076-9d2b-76a8-843e-6686f2efe993",
  "docSlug": "264dd70dbc5f8f6fdd2a3dbf6f8c09b5",
  "documentTitle": "Exscientia | Investor Day Presentation Deck | 90 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 87,
  "pageCount": 90,
  "prevPage": 86,
  "nextPage": 88,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The table uses color-coding (red/green) to highlight risk levels for UGT1A1 inhibition parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9d2b-76a8-843e-6686f2efe993/87",
  "deckHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993",
  "deckJsonHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993.json",
  "deckAnchorHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993#slide-87",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "We predict that selectivity over UGT1A1 could be an issue for some clinical stage MALT1 inhibitors. Inhibition of UGT1A1 mediates bilirubin glucuronidation, potentially leading to hyperbilirubinaemia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59bc253d-ff28-44ed-8cee-05b873868827",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "list",
      "text": "‘565 has a low risk of potential DDI/ hyperbilirubinaemia at predicted human efficacious doses. Potential for safer dose escalation for ‘565 to reach the level of target engagement necessary to achieve clinical efficacy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8a2ce64-b527-496b-9c98-4ab52e0c7097",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Payne et al. ESMO, 2023. 1) Hertzberg et al. Hematol Oncol, 2023; Cmax,u: Predicted maximum free plasma; Imax,u,inlet: free liver inlet concentration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc9e06cf-b02b-4aa1-beec-71d6f9cd02a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.6
      },
      "kind": "table",
      "text": "Comparison table of Pharma Phase 1b vs '565 across UGT1A1 metrics (IC50, IC50/Imax, Rfree, Rin,free, Fi) and final risk prediction.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fd2c9cd-35b7-44d6-9066-ac1334b73638",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Potential safety benefit compared with clinical MALT1i in development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d87ea9be-25de-413d-ae61-3e6affafb7b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565 has a low predicted risk of hyperbilirubinaemia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "667a06ae-4c1b-4c18-b795-11ce50e3cd87",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "0836cba2-7240-44e9-8455-3fe9c1f7825e",
      "evidence": "Comparison table of Pharma Phase 1b vs '565 across UGT1A1 metrics",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 90,
      "from": 21,
      "beatId": "08c298bd-8dc4-4aa8-832d-c7b35097d152",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The presentation deck ends with a call to action, encouraging investors to take action",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}